Evidence map›Paper›PMID 36109411›Full record

ReviewAnnals of surgical oncology2022

Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer.

Giovanni Corso, Francesca Magnoni, Paolo Veronesi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Prevalence of GermlineCancers · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giovanni CorsoDivision of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy. giovanni.corso@ieo.it.ORCID http://orcid.org/0000-0002-9269-0146
Francesca MagnoniDivision of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Paolo VeronesiDivision of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For women affected by breast cancer who carry germline BRCA1/2 pathogenic variants, the classic standard treatment consists of therapeutic unilateral mastectomy and risk-reducing contralateral mastectomy. However, data from recent literature demonstrate that for women treated with breast-conserving surgery who receive adequate adjuvant treatments, the increased risk of locoregional recurrences and a breast cancer-related prognosis is not significant. This review describes the clinical factors that could help clinicians decide either against or in favor of a more aggressive type of breast cancer surgery.

Indexed as

Breast NeoplasmsMastectomyFemaleHumansMastectomy, SegmentalNeoplasm Recurrence, LocalPrognosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.